Cathie Wood Jounce Therapeutics, Inc. Transaction History

Ark Investment Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 07, 2018	SELL	$7.27 - $21.88 $677,149 - $2.04 Million	-93,143 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$13.4 - $28.4 $535,557 - $1.14 Million	39,967 Added 75.16%	93,143 $2.08 Million
Q4 2017 Feb 12, 2018	BUY	$12.52 - $17.82 $308,542 - $439,156	24,644 Added 86.37%	53,176 $678,000
Q3 2017 Nov 09, 2017	BUY	$11.17 - $16.99 $185,422 - $282,034	16,600 Added 139.12%	28,532 $445,000
Q2 2017 Aug 11, 2017	BUY	N/A	10,121 Added 558.86%	11,932 $167,000
Q1 2017 May 15, 2017	BUY	N/A	1,811	1,811 $40,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Ark Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Ark Investment Management LLC and Cathie Wood with notifications on news.